Atsena Therapeutics

DURHAM, N.C., July 9, 2026 Atsena Therapeutics announced the selection of ATSN-401 as its lead clinical candidate for the...

DURHAM, N.C., May 7, 2026 Atsena Therapeutics announced positive new clinical data from its investigational gene therapy programs ATSN-201...